{"id":"prepandrix","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"1-5","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL6068363","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated H5N1 influenza virus particles that have been chemically treated and split to reduce reactogenicity while preserving immunogenicity. Upon administration, these viral antigens are recognized by the immune system, triggering both humoral (antibody) and cellular immune responses that provide protection against infection with H5N1 influenza. The vaccine was developed in preparation for potential pandemic influenza outbreaks caused by H5N1 strains.","oneSentence":"Prepandrix is an inactivated split-virion influenza vaccine that stimulates the immune system to produce antibodies against pandemic H5N1 influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:28.680Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pandemic influenza H5N1 prevention in adults"}]},"trialDetails":[{"nctId":"NCT01730378","phase":"PHASE4","title":"Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-05","conditions":"Influenza","enrollment":131}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GlaxoSmithKline [GSK] Biologicals' A/Indonesia/5/2005 (H5N1) (pre-) pandemic influenza adjuvanted vaccine"],"phase":"marketed","status":"active","brandName":"Prepandrix™","genericName":"Prepandrix™","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Prepandrix is an inactivated split-virion influenza vaccine that stimulates the immune system to produce antibodies against pandemic H5N1 influenza virus strains. Used for Pandemic influenza H5N1 prevention in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}